Key Highlights

  • AVITA Medical shares touched a 52-week high during the session on Monday 9 November 2026 and closed at $4.89, up 7.47%.
  • Q3 2026 total Revenue rose 53% year on year to $26.1 million, and 20% on the prior quarter.
  • Gross Margin was 84.0%, up 270 basis points, and the company raised its full-year 2026 revenue guidance.

AVITA Medical, Inc. (ASX:AVH) touched a 52-week high during the Trading session on Monday, 9 November 2026, and closed at $4.89, up 7.47%. AVITA is a wound care company whose products include RECELL and Cohealyx, and it is listed on Nasdaq and the ASX.

Latest Development: Q3 2026 Results, 5 November 2026

AVITA Medical reported third quarter 2026 results on 5 November 2026. Total revenue rose 53% year on year and 20% sequentially to $26.1 million, driven by RECELL and increasing use of Cohealyx.

Gross margin was 84.0%, up 270 basis points year on year, and operating expenses were $24.6 million, flat on the prior quarter. Net cash use improved to about $0.6 million.

The company raised its full-year 2026 revenue guidance following the quarter.

About the Company

AVITA develops regenerative wound care products, including RECELL autologous skin cell suspension, and sells them to hospitals and burn and wound care clinics.

Sector Context

Regenerative wound care depends on hospital purchasing, reimbursement and clinician adoption, which shape the speed of revenue growth.

Risks and What to Watch Ahead

Performance-based compensation rose with commercial growth, and the company must sustain adoption to maintain margins. Reimbursement decisions remain a factor.

Watch items include fourth quarter revenue, the full-year guidance outcome and Cohealyx adoption.

Final Word

AVITA's Q3 report shows revenue growth of 53%, a higher gross margin and an improved cash use figure, alongside a raised full-year revenue outlook.